6/16 Late treatment study
et al., Korean J Intern Med, doi:10.3904/kjim.2020.224 (Peer Reviewed)
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
Small retrospective study of hospitalized patients with 31 lopinavir-ritonavir and 34 HCQ patients, HCQ 400mg once per day, finding no significant difference in clinical response, but more rapid viral clearance with lopinavir-ritonavir.
Kim et al., 6/16/2020, retrospective, South Korea, Asia, peer-reviewed, 7 authors.
